At a dangerous point in the Ebola outbreak, residents increase cooperation with containment efforts

The people living in the current Ebola hot spot in the DRC are beginning to comprehend more fully the danger the virus poses — a welcome development in an outbreak…
A man displays an Ebola information leaflet for residents in Mangina, Democratic Republic of Congo. Source: Al-hadji Kudra Maliro/AP

The Ebola outbreak in the Democratic Republic of the Congo has reached a dangerous phase, with the response operation acknowledging it hasn’t got a full picture of where the virus is spreading in a large urban center.

That concerning development is tempered slightly by signs that people living in Beni, the current hot spot of transmission, are beginning to comprehend more fully the danger the virus poses, said a senior World Health Organization official.

That understanding is translating into better cooperation — a welcome development in an outbreak response that has had more than its share of bad luck.

“There is underground community transmission in Beni. It may not be at a very intense level. But it is enough to continue and drive transmission in this

You're reading a preview, sign up to read more.

More from STAT

STAT1 min readWellness
STAT Plus: Pharmalittle: France Piles Pressure On Sanofi Over Covid-19 Vaccine; GOP Fails To Land A Punch On Bright
Under an “America First” president, public health experts worry the U.S. could seek to gobble up early supplies of Covid-19 vaccine.
STAT1 min readSociety
STAT Plus: Pharmalittle: Coronavirus Vaccine May Not Be A Cure-all; Hydroxychloroquine Fails In A Covid-19 Study
#Covid19 vaccines in development may be more like those that protect against influenza — reducing the risk of contracting the disease and of experiencing severe symptoms should infection occur.
STAT1 min readSociety
STAT Plus: Pharmalittle: Administration Mishandled Initial Remdesivir Distribution; AstraZeneca Lung Cancer Drug Shows Big Benefit
The Trump administration mishandled the initial distribution of remedesivir, the experimental Gilead Sciences Covid-19 medicine, delaying treatment to some critically ill patients.